Banoxantrone dihydrochloride

Key Product Details

Product Description

Banoxantrone dihydrochloride is a bioreductive prodrug; activated by hypoxia to yield the topoisomerase II inhibitor AQ4. Displays little to no cytotoxic activity against 60 tumor cell lines tested under oxic conditions (IC₅₀ >100 μM). Exhibits anti-tumor efficacy in vivo when combined with oxic cell cytotoxins; enhances the anti-tumor effect of cyclophosphamide (Cat. No. 4091) in a mouse tumor model.

Product Specifications for Banoxantrone dihydrochloride

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Banoxantrone dihydrochloride

The following data is based on the product molecular weight 517.40.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	3.87 mL	19.33 mL	38.65 mL
2.5 mM	0.77 mL	3.87 mL	7.73 mL
5 mM	0.39 mL	1.93 mL	3.87 mL
25 mM	0.08 mL	0.39 mL	0.77 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Patterson and McKeown AQ4N: a new approach to hypoxia-activated cancer chemotherapy. Br.J.Cancer 2000 PMID: 11104551
• Mehibel Effects of cytokine-induced macrophages on the response of tumor cells to banoxantrone (AQ4N). Mol.Cancer Ther. 2009 PMID: 19435866
• Friery Enhancement of the anti-tumour effect of cyclophosph. by the bioreductive drugs AQ4N and tirapazamine. Br.J.Cancer 2000 PMID: 10780528

Product Documents for Banoxantrone dihydrochloride